An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Moura, Líbia C R V ^a   Ximenes, Ricardo A A ^a,b   Ramos, Heloísa L ^a   Miranda Filho, Demócrito B ^b   Freitas, Carolina D P ^a   Silva, Rosangela M S ^c   Coimbra, Isabella ^a   Batista, Joanna D'Arc L ^c   Montarroyos, Ulisses R ^a   Militão Albuquerque, Maria De Fátima P ^c  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; BRAZIL; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; MALE; PATIENT ATTITUDE; SEX DIFFERENCE; SOCIOECONOMICS; STATISTICS; TUBERCULIN TEST; UTILIZATION REVIEW;

ADULT; AGE FACTORS; BRAZIL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LATENT TUBERCULOSIS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; SEX FACTORS; SOCIOECONOMIC FACTORS; TUBERCULIN TEST;

EID: 80052567891     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-687     Document Type: Article

References (57)

1. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo CM, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC, AIDS 2001 15 2137 47 10.1097/00002030-200111090-00009 11684933 (Pubitemid 33101821)
2. The Growing burden of tuberculosis. Corbett EI, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C, Arch Intern Med 2003 163 1009 21 10.1001/archinte.163.9.1009 12742798 (Pubitemid 36548927)
3. Co-infection with HIV and TB: double trouble. McShane H, Intern J of STD & AIDS 2005 16 95 101 10.1258/0956462053057576 (Pubitemid 40313201)
4. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa. A novel randomized incremental recruitment study. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, De cock KM, Hayes RJ, Churchyard GJ, JAMA 2005 293 22 2719 25 10.1001/jama.293.22.2719 15941800 (Pubitemid 40965083)
5. Operational research for improved tuberculosis control: the scope, the needs and the way forward. Lienhardt C, Cobelens FGJ, Int J Tuberc Lung Dis 2011 15 1 6 13 21276290
6. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. Churchyard GJ, Scano F, Grant AD, Chaisson RE, The J of Infec Dis 2007 196 552 62
7. Undiagnosed tuberculosis in a community with high HIV prevalence. Implications for tuberculosis control. Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, Mcintyre J, Belcker LG, Am J of Respir and Crit Care Med 2007 175 87 93 (Pubitemid 46105314)
8. Early mortality and cause of deaths in patients using HAART in Brazil and United States. Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM, Campos DP, Pilotto JH, Cardoso SW, Keruly JC, Moore RD, AIDS 2009 23 1 7 10.1097/QAD.0b013e3283217f63 19050379
9. Synergistic pandemics: confronting the global HIV and tuberculosis epidemics. Mayer KH, Hamilton CD, CID 2010 50 3 567 70
10. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, Ippolito G, GISTA, AIDS 2000 14 1985 91 10.1097/00002030-200009080-00015 10997404
11. Restoration of cellular immunity against tuberculosis in patients co-infected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation. Hsieh SM, Hung CC, Pan SC, Wang JT, Tsai HC, Chen MY, Chang SC, J Acquir Immune Defic Syndr 2000 25 212 20 10.1097/00126334-200011010-00002 11115951
12. High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. Girard E, Palmiere F, Zaccarelli M, Tozzi V, Trotta MP, Selva C, Narciso P, Petrosillo N, Antinori A, Ippolito G, AIDS 2002 16 14 1976 9 10.1097/00002030-200209270-00021 12351964
13. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. Lawn SD, Bekker LG, Wood R, AIDS 2005 19 1113 24 10.1097/01.aids.0000176211.08581.5a 15990564 (Pubitemid 41059253)
14. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV cohort study. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A, JAMA 1999 282 2220 6 10.1001/jama.282.23.2220 10605973 (Pubitemid 30002965)
15. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The adult/adolescent spectrum of HIV disease group. Jones JL, Hanson DL, Dworkin MS, De Cock KM, Int J Tuberc Lung Dis 2000 4 1026 31 11092714
16. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Austrália. Dore GJ, Li Y, McDonald A, Ree H, Kaldo JM, JAIDS J Acquir Immune Defic Syndr 2002 29 388 95 (Pubitemid 34288893)
17. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Santoro-Lopes G, Pinho AMF, Harrison LH, Schechter M, CID 2002 34 543 6 10.1086/338641 (Pubitemid 34112278)
18. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Williams BG, Dye C, Science 2003 301 1535 7 10.1126/science.1086845 12920302 (Pubitemid 37128545)
19. Evaluacián de dos pautas de quimioprofilaxis tuberculoa em pacientes infectdos por el vírus de la inmunodeficiência humana. Alfaro EM, Cuadra F, Solera J, Maciá MA, Geijo P, Martinez PAS, Zapata MR, Largo J, Sepúlveda MA, Rosa C, Sánchez L, Espinosa A, Mateos F, Blanch, Medicina Clínica 2000 115 161 5 21894404
20. Risk factors for development of Tuberculosis after Isoniazid Chemoprophylaxis in Human Immunodeficiency Virus-Infected Patients. Casado JL, Moreno S, Fortin J, Antela A, Quereda C, Navas E, Moreno A, Dronda F, CID 2002 34 386 9 10.1086/324746 (Pubitemid 34062241)
21. Randomised trai of isosiazid versus rifampicin and pyrazinamide for of tuberculosis in HIV-1 infection. Halsey NA, Coberly JS, Desoumeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE, The lancet 1998 351 786 792 10.1016/S0140-6736(97)06532-X (Pubitemid 28112340)
22. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. Mwinga A, Hops M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, McAdam KPWJ, Poeter JDH, et al. AIDS 1998 l2 2447 2457 (Pubitemid 28558603)
23. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. Pinho AMF, Santoro-Lopes G, Harrison LH, Schechter M, AIDS 2001 15 2129 35 10.1097/00002030-200111090-00008 11684932 (Pubitemid 33101820)
24. Grupo Andaluz para el studio de las enfermedades infecciosas. Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infeccián latente tuberculosa en pacientes infectados por el VIH. Rivero A, Lápez-Cortés L, Castillo R, Verdejo J, Garcia MA, Martinez-Marcos FJ, Diez F, Escribano JC, Canueto J, Lozano F, Pasquau J, Hernandez JJ, Marquez M, Kindelán JM, Enferm Infecc Microbiol Clin 2007 25 5 305 10 10.1157/13102265 17504683 (Pubitemid 47202768)
25. Grupo Andaluz para el studio de las enfermedades infecciosas. A randomized Trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy. Rivero A, Lápes-Cortez L, Castillo R, Lozano F, Garcia MA, Diez F, Escribano JC, Canueto J, Pasquau J, Hernandez JJ, Polo R, Martínez-Marcos FJ, Kindelán JM, Rey R, Enferm Infecc Microbiol Clin 2003 21 6 287 292 10.1157/13048575 12809582 (Pubitemid 36869935)
26. Stop TB department and department of HIV/AIDS. World Health Organization, Interim Policy on collaborative TB/HIV activities Geneva 2004
27. Policy statement on preventive therapy against tuberculosis in people living with HIV. World Health Organization, Global tuberculosis programme and UNAIDS, Report of a meeting held in Geneva 18-20 February 1998 Geneva 1998
28. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H, The Swiss HIV Cohort Study, CID 2007 44 94 102 10.1086/510080 (Pubitemid 44968992)
29. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ, The New Engl J Med 1997 12 801 8 (Pubitemid 27391629)
30. Effect of isoniazida prophylaxis on incidence of active tuberculosis and progression of HIV infection. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr, The Lancet 1993 31 268 72 (Pubitemid 23224420)
31. Treatment of latent tuberculosis infection in HIV infected persons. Akolo C, Adetifa I, Shepperd S, Volmink J, Cochrane Database of Systematic Reviews 2010 1 D000171
32. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society/Centers for Disease Control and Prevention, Am J Respir Crit Care Med 2000 161 5221 47
33. Control and prevention of tuberculosis in United Kingdom: code of practice 2000. British Thoracic Society, Joint tuberculosis committee of British thoracic society, THORAX 2000 55 887 901 10.1136/thorax.55.11.887 11050256
34. BCG coverage and the annual risk of tuberculosis infection over a 14-year period in the Philippines assessed from the nationwide prevalence surveys. Tupasi TE, Radhakrishna S, Pascual MLD, Quelapio MI, Villa ML, Co VM, Sarol J, Mangubat N, Reyes AC, Sarmiento A, Solon M, Solon F, Burton L, Lofranco VS, Rostrata MPC, Mantala MJ, Int J Tuberc Lung Dis 2000 4 216 22 10751066 (Pubitemid 30151568)
35. Risk of tuberculosis infection an tuberculous meningitis after discontinuation of Bacillus Calmette-Guerin in Beijing. Zhang LX, Tu DH, He GX, Ma ZQ, Nagelkerke NJ, Borgdorff MW, Enarson DA, Broekmans JF, Am J Respir Crit Care Med 2000 162 1314 7 11029337
36. Global surveillance for antituberculosis-drug resistance. Pablos-Mendes A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Weezenbeek CSB, Kim SJ, Chaulet P, Nunn P, N Engl J Med 1998 338 1641 9 10.1056/NEJM199806043382301 9614254 (Pubitemid 28267908)
37. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJC, Churchyard GJ, Grant AD, AIDS 2010 24 1 5 10.1097/QAD.0b013e328333acfb 19890206
38. Isoniazid for preventing tuberculosis in non-HIV infected persons (cochrane review). Smieja MJ, Marchetti CA, Cook DJ, Smaill FM, The cochrane library Oxford. Update software 2008 2
39. Treatment of latent tuberculosis infection in HIV infected persons (cochrane review). Woldehanna S, Volmik J, The cochrane library Oxford. Update software 2006 1
40. Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity. Dodd PJ, Millington KA, Ghani AC, Mutsvangwa Junior, Butterworth AE, Lalvani A, Corbett EL, Am J Epidemiol 2010 171 1037 45 10.1093/aje/kwq017 20382638
41. Tuberculose e infecção pelo HIV no Brasil: magnitude do problema e estratégias para o controle. Jamal FF, Moherdaui F, Rev Saúde Pública 2007 41 1 104 10 21399266
42. Brasil, Ministério da Saúde, Secretaria de Vigilncia Sanitária, Tuberculose. Guia de vigilncia epidemiolágica Brasília 2009
43. III Diretrizes para tuberculose da sociedade brasileira de pneumatologia e tisiologia. Conde MB, Melo FAF, Marques AMC, Cardoso NC, Pinheiro VGF, Dalcin PTR, et al. J Bras Pneumol 2009 35 10 1018 48 19918635
44. Programa Nacional de DST e Aids. Guia de tratamento. Brasil, Ministério da Saúde, Secretaria de Vigilncia em Saúde, Recomendaçes para terapia anti-retroviral em adultos infectados pelo HIV Brasília 2008
45. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brasil. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B, AIDS 2007 21 1441 48 10.1097/QAD.0b013e328216f441 17589190 (Pubitemid 46988004)
46. Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-saharan Africa. Nuwaha F, East African Med J 1998 9 75 520 7 (Pubitemid 128385799)
47. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counseling and testing center. Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Engwau FA, AIDS 1995 9 267 73 7755915
48. Guidelines for intensified tuberculosis case finding and isoniazida preventive therapy for people living with HIV in resource constrained settings. World Health Organization, Stop TB department and department of HIV/AIDS Geneva WHO 2011
49. Tuberculose-Casos confirmados notificados no Sistema de informação de Agravos de Notificação-SINAN. Brasil, Ministério da, Saúde, DATASUS/MS/SUS, http://www2.datasus.gov.br/ DATASUS/index.php?area=01 Accessed march 25, 2010.
50. Poor concordance between interferon- release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, Blumberg HM, BMC Infectious Diseases 2009 9 15 24 10.1186/1471-2334-9-15 19208218
51. Underestimation of Mycobacterium tuberculosis infection in HIV-infected subjects using reactivity to tuberculin and anergy panel. Garcia-Garcia ML, Valdespino-Gomez JL, Garcia-Sancho C, Mayar-Maya ME, Palácios-Martinez M, Balandrano-Campos S, Escobar-Guitiérrez A, Peruga A, Weissenbacher M, Daniels E, Int J Epidemiol 2000 29 369 75 10.1093/ije/29.2.369 10817138 (Pubitemid 30209832)
52. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina E, J Acquir Immune Defic Syndr 2006 42 464 9 10.1097/01.qai.0000225729.79610.b7 16810113 (Pubitemid 44050895)
53. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. Wood R, Maartens G, Lombard CJ, J Acquir Immune Defic Syndr 2000 23 75 80 10708059 (Pubitemid 30123268)
54. Preventive therapy for tuberculosis in HIV infected individuals. Padmapriyadarsini C, Swaminathan S, Indian J Med Res 2005 121 415 23 15817954 (Pubitemid 40691374)
55. Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts. Long R, Houston S, Hershfield E, CMAJ 2003 169 789 91 14557318 (Pubitemid 37305117)
56. Feasibility of an emergency department-based tuberculosis counseling and screening program. Kirsh TD, Chanmugam A, Keyl P, Regan LA, Sharan J, Hexter DA, Kelen GD, Acad Emerg Med 1999 6 224 31 10.1111/j.1553-2712.1999.tb00161.x 10192675 (Pubitemid 29118163)
57. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD, J Acquir Immune Defic Syndr Hum Retrovirol 1996 11 5 455 9 10.1097/00042560-199604150-00005 8605590 (Pubitemid 26135082)